Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus
暂无分享,去创建一个
[1] Y. Natkunam,et al. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis , 2020, International journal of molecular sciences.
[2] I. Chaban,et al. Distinct Differentiation Characteristics of Endothelium Determine Its Ability to Form Pseudo-Embryos in Tomato Ovules , 2019, International journal of molecular sciences.
[3] M. Infantino,et al. European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.
[4] D. Gladman,et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.
[5] D. Gladman,et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.
[6] H. Matsuoka,et al. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin , 2019, Annals of Hematology.
[7] R. Suzuki,et al. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL) , 2019, International Journal of Hematology.
[8] Le-Bin Song,et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis , 2018, Arthritis Research & Therapy.
[9] A. Polliack,et al. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. , 2018, Leukemia research.
[10] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[11] S. Bernatsky,et al. A review on SLE and malignancy. , 2017, Best practice & research. Clinical rheumatology.
[12] H. Sasano,et al. Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture , 2017, Leukemia & lymphoma.
[13] S. Bernatsky,et al. Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.
[14] D. Heo,et al. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities , 2015, Leukemia & lymphoma.
[15] G. Houen,et al. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients , 2015, Scandinavian journal of rheumatology.
[16] Sang‐wook Lee,et al. Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study , 2014, Annals of Hematology.
[17] A. Avenell,et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus , 2014, Arthritis Research & Therapy.
[18] D. Gladman,et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment , 2012, Annals of the rheumatic diseases.
[19] D. Gladman,et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. , 2013, Journal of autoimmunity.
[20] T. Yoshino,et al. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Sang‐wook Lee,et al. Clinical features and prognostic model for extranasal NK/T‐cell lymphoma , 2012, European journal of haematology.
[22] R. Suzuki. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia , 2010, International journal of hematology.
[23] M. Mok,et al. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus , 2010, Lupus.
[24] K. Ohshima,et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Weisenburger,et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. , 2009, Blood.
[26] K. Costenbader,et al. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL) , 2007, Clinical Rheumatology.
[27] Lee Hebert,et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.
[28] Kong-Chao Chang,et al. EBER-1 positive diffuse large cell lymphoma presenting as lupus nephritis , 2003, Lupus.